Nalaganje...
Optimizing clinical trial design for multiple system atrophy: lessons from the rifampicin study
Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by autonomic failure and parkinsonism/ataxia; no treatment exists to slow disease progression. A number of factors have prevented or compromised trials targeting disease modification. A major hurdle has been uncertaint...
Shranjeno v:
| izdano v: | Clin Auton Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4763681/ https://ncbi.nlm.nih.gov/pubmed/25763826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10286-015-0281-2 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|